Neuroblastoma: paradigm for precision medicine

Area of Science:

• Pediatric Oncology
• Cancer Biology
• Clinical Trials

Background:

• Neuroblastoma (NB) is the third most common pediatric cancer.
• NB accounts for 7% of pediatric malignancies but over 10% of childhood cancer mortality.
• Prognosis and treatment strategies are dictated by clinical and biological risk factors.

Purpose of the Study:

• To outline the current landscape of neuroblastoma treatment.
• To differentiate therapeutic approaches based on risk stratification.
• To highlight the disparity in survival rates between non-high-risk and high-risk neuroblastoma.

Main Methods:

• Review of recent clinical trial data for neuroblastoma.
• Analysis of risk stratification factors influencing treatment decisions.
• Comparison of treatment modalities for different risk groups.

Main Results:

• Estimated 5-year survival rates exceed 90% for non-high-risk NB and are less than 50% for high-risk NB.
• Therapy reduction and observation are employed for favorable non-high-risk NB subsets.
• High-risk NB patients undergo aggressive multimodal therapy including chemotherapy, radiation, surgery, and immunotherapies.

Conclusions:

• Risk stratification is crucial for tailoring neuroblastoma treatment.
• Aggressive multimodal therapy is essential for improving outcomes in high-risk neuroblastoma.
• Ongoing research aims to refine treatment strategies for all neuroblastoma patient groups.